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ABSTRACT
ObjeCtive
To develop and validate a risk prediction model for 
venous thromboembolism in the first six weeks after 
delivery (early postpartum).
Design
Cohort study.
setting
Records from England based Clinical Practice Research 
Datalink (CPRD) linked to Hospital Episode Statistics 
(HES) and data from Sweden based registry.
PartiCiPants
All pregnant women registered with CPRD-HES linked 
data between 1997 and 2014 and Swedish medical 
birth registry between 2005 and 2011 with postpartum 
follow-up.
Main OutCOMe Measure
Multivariable logistic regression analysis was used to 
develop a risk prediction model for postpartum venous 
thromboembolism based on the English data, which 
was externally validated in the Swedish data.
results
433 353 deliveries were identified in the English cohort 
and 662 387 in the Swedish cohort. The absolute rate 
of venous thromboembolism was 7.2 per 10 000 
deliveries in the English cohort and 7.9 per 10 000 in 
the Swedish cohort. Emergency caesarean delivery, 
stillbirth, varicose veins, pre-eclampsia/eclampsia, 
postpartum infection, and comorbidities were the 
strongest predictors of venous thromboembolism in 
the final multivariable model. Discrimination of the 
model was similar in both cohorts, with a C statistic 
above 0.70, with excellent calibration of observed and 
predicted risks. The model identified more venous 
thromboembolism events than the existing national 
English (sensitivity 68% v 63%) and Swedish 
guidelines (30% v 21%) at similar thresholds.
COnClusiOn
A new prediction model that quantifies absolute risk of 
postpartum venous thromboembolism has been 
developed and externally validated. It is based on 
clinical variables that are available in many developed 
countries at the point of delivery and could serve as 
the basis for real time decisions on obstetric 
thromboprophylaxis.
Introduction
The risk of venous thromboembolism increases signifi-
cantly during pregnancy, peaks during the postpartum 
period, and is one of the leading causes of maternal 
mortality in developed countries.1 2  In the United King-
dom, 50% of venous thromboembolism related mater-
nal deaths occur during the postpartum period.2 
Targeted thromboprophylaxis can prevent postpartum 
venous thromboembolism with minimum harm; how-
ever, variations exist in the threshold (set on the basis 
of certain risk factors) at which intervention is recom-
mended.3-6 Although risk factors such as previous 
venous thromboembolism and certain thrombophilias 
are recognised as warranting intervention on their own, 
women with these risk factors represent a small propor-
tion of all women giving birth. The vast majority of post-
partum venous thromboembolisms occur in women 
without these specific risk factors.
Recommendations for thromboprophylaxis among a 
large proportion of postpartum women with only one or 
more “low to moderate” risk factors (such as obesity, 
caesarean section, and postpartum haemorrhage) are 
inconsistent across countries.3-6  In the UK, women are 
categorised into low, intermediate, and high risk groups 
in the postpartum period with respect to advice on the 
duration of pharmacological thromboprophylaxis 
according to an additive ordinal point based scoring 
system,5  which is not externally validated. A similar 
system is used in Sweden,6  which is more conservative 
than those in the UK and Canada. Such categorisation, 
although visually pleasing and easily implemented in 
practice, may disguise the large variation in the actual 
risk of venous thromboembolism in those risk groups. 
Using a model to make predictions for individual 
women is thus more accurate and is preferred to the 
risk grouping approach.7  8
The aim of our study was to develop and externally 
validate a new prediction model that can generate 
absolute predicted risk of first venous thromboembo-
lism within the first six weeks postpartum on the basis 
WhAT IS AlReAdy knoWn on ThIS TopIC
The risk of venous thromboembolism (VTE) peaks during the first six weeks after 
delivery (postpartum) and is one of the leading causes of maternal mortality in 
developed countries
Targeted thromboprophylaxis can prevent VTE, but clinical risk prediction of VTE in 
postpartum women is rudimentary
WhAT ThIS STudy AddS
A risk prediction model has been developed and externally validated
This can be used as a tool to identify women at high risk of VTE, as it provides a 
woman’s individual absolute predicted risk within the first six weeks postpartum.
The model is based on clinical variables that are likely to be available at the point of 
childbirth and performed better than the UK and Swedish thromboprophylaxis guidelines
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of each woman’s individualised clinical risk profile, and 
to compare this with the existing UK guideline on 
thromboprophylaxis from the Royal College of Obstetri-
cians and Gynaecologists (RCOG) and the Swedish 
guideline.5 6
Methods
Data sources and study population
For this study, we used data from England to develop 
our postpartum venous thromboembolism risk score 
and data from Sweden to externally validate it. We have 
previously published the incidence of venous thrombo-
embolism in both obstetric populations (England and 
Sweden) and found comparable estimates.9 10
Derivation cohort (England)
The Clinical Practice Research Datalink (CPRD) is a 
large, longitudinal UK primary care database that cov-
ers 6% of the population.11  Approximately 98% of the 
UK population are registered with general practitioners, 
who are responsible for almost the entirety of a patient’s 
medical care.12 All general practitioners participating in 
the CPRD are trained to record information by using the 
general practice Vision software. More than 50% of 
CPRD practices are linked to Hospital Episode Statistics 
(HES), which contains information on all hospital 
admissions in England. The anonymised patient identi-
fiers from CPRD and HES have been linked by a trusted 
third party using NHS number, date of birth, postcode, 
and sex. Firstly, patients are matched on the basis of 
their NHS number (more than 90% of patients are 
linked in this way). The remaining patients are then 
linked probabilistically on postcode, date of birth, and 
sex. As HES covers only English hospitals, we excluded 
practices in Northern Ireland, Wales, and Scotland. To 
develop our risk prediction model, we used data on 
women (registered with a CPRD-HES linked practice) 
with no previous history of venous thromboembolism 
whose pregnancy ended in live birth or stillbirth 
between 1997 and 2014 and who had at least six weeks’ 
postpartum follow-up.
Validation cohort (Sweden)
The Swedish national inpatient register (IPR) was estab-
lished in 1965 and has had complete national coverage 
since 1987.13  More than 99% of all somatic and psychiat-
ric hospital discharges from across Sweden are regis-
tered in the inpatient register. From 2001, IPR also 
includes hospital based outpatient consultations. Diag-
noses in IPR are coded according to the Swedish inter-
national classification of disease system. It is mandatory 
for all physicians (private and publically funded) to 
deliver data to the IPR. Each hospital discharge and out-
patient consultation is keyed to an individual’s unique 
personal identity number,14  which is issued to every 
individual in Sweden. The number is based on the com-
bination of date of birth and a four digit number and is 
used by various private and public sectors to identify 
each individual. It is also used by the National Board of 
Health and Welfare to link data across various registers 
at the individual level. The Swedish Medical Birth 
 Registry (SBR) contains information on more than 98% 
of all delivery records in Sweden since 1973. The SBR 
has been subjected to many quality checks, and the 
recorded data are of high quality and reliable.15 16 For 
the purpose of validating a postpartum thrombosis risk 
score, we included information on pregnancies in 
women with no history of venous thromboembolism 
resulting in a live birth or stillbirth between 1 July 2005 
and 31 December 2011. Using data from 2005 onwards 
allowed the acquisition of the national prescription 
data (National Prescribed Drug Register) for all of the 
Swedish study population.
Defining venous thromboembolism
We defined our outcome as the occurrence of a first 
venous thromboembolism (deep venous thrombosis or 
pulmonary embolism) within the first six weeks after 
delivery. In both our derivation and validation cohorts, 
we defined venous thromboembolism by using an algo-
rithm externally validated in the UK’s primary care data 
with high accuracy (positive predictive value 84%).17 
Briefly, the algorithm considered a diagnosis of venous 
thromboembolism to be valid if it was accompanied by 
a prescription for an anticoagulant within 90 days of 
the event or if the patient died within 30 days of the 
event. This definition has also been shown to produce 
estimates of venous thromboembolism during the ante-
partum and postpartum periods in both English and 
Swedish data that are comparable to existing literature 
on the subject.9 10
Candidate predictors, missing data, and power 
calculations
For each pregnant woman, we extracted information on 
sociodemographic and lifestyle characteristics, pre-ex-
isting comorbidities, and characteristics and complica-
tions of pregnancy and delivery from the medical 
record.18  Definitions and the international classifica-
tion of disease (ICD) codes used for each predictor are 
summarised in supplementary tables A and B. Primar-
ily, we selected our candidate predictors from the most 
recent version of the RCOG’s thromboprophylaxis 
guidelines.5  These guidelines are already based on 
extensive literature review and expert consensus in 
opinion. We also added predictors not included in the 
guideline but identified in previous studies as import-
ant obstetric risk factors for venous thromboembolism 
that we were able to measure reliably in our data. These 
included diabetes, hypertension, and infant birth 
weight.19-21 We measured antenatal parity that did not 
include current birth to avoid confusion about chang-
ing parity status during the course of pregnancy and 
allow for a standardised measure of parity during both 
antepartum and postpartum periods. For instance, a 
woman considered nulliparous during her first antena-
tal visit will remain in that category through the course 
of that pregnancy and the subsequent postpartum 
period and will be considered to have parity 1 for her 
subsequent pregnancy.
Our derivation cohort had missing information on 
pre-pregnancy body mass index (23%) and infant birth 
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weight (20%). We used multiple imputation to replace 
missing values by using a chained equation approach 
based on all candidate predictors. We created 10 
imputed datasets for missing variables that were then 
combined across all datasets by using Rubin’s rule to 
obtain final model estimates. Using the same method, 
we also imputed values for women with missing infor-
mation on pre-pregnancy body mass index or their 
infant’s birth weight (8.6%) in our Swedish validation 
cohort. On the basis of an estimated 300 venous throm-
boembolism events during the first six weeks postpar-
tum and 22 candidate predictors in our derivation 
cohort, we had an effective sample size of 14 venous 
thromboembolism events per predictor, above the min-
imum requirement suggested by Peduzzi et al.22
statistical analysis for model development and 
validation
We treated occurrence of venous thromboembolism 
during the first six weeks postpartum as a binary out-
come measure. For each of the 22 candidate predictors, 
we used a univariable logistic regression model to cal-
culate the unadjusted odds ratio. For derivation of the 
risk prediction model, we initially included all 
 candidate predictors in a multivariable logistic regres-
sion model. We fitted a clustering term to take account 
of consecutive pregnancies within women during the 
study period and used fractional polynomials to model 
potential non-linear relations between outcome and 
continuous predictors.
Through backwards elimination, we excluded 
(except for age at delivery, which was considered a prior 
predictor and retained in the model regardless of statis-
tical significance23) candidate predictors from the 
 multivariable model that were not statistically signifi-
cant (P>0.1 based on change in log likelihood). After 
elimination, we reinserted excluded predictors into the 
final model to further check whether they became sta-
tistically significant. We also rechecked fractional poly-
nomial terms at this stage and re-estimated them if 
necessary. We formed the risk equation for predicting 
the log odds of venous thromboembolism by using the 
estimated β coefficients multiplied by the correspond-
ing predictors included in our model together with the 
average intercept across patient clusters. This process 
ultimately led to an equation for the predicted absolute 
risk of venous thromboembolism: predicted risk=1/
(1+e−riskscore), where the “risk score” is the predicted log 
odds of venous thromboembolism from the developed 
model.
We assessed the performance of the model in terms of 
the C statistic and calibration slope (where 1.00 is 
ideal). The C statistic represents the probability that for 
any randomly selected pair of women with and without 
a venous thromboembolism, the women who had a 
venous thromboembolism had a higher predicted risk.24 
A value of 0.50 represents no discrimination and 1.00 
represents perfect discrimination. We then did internal 
validation to correct measures of predictive perfor-
mance for optimism (over-fitting) by bootstrapping 100 
samples of the derivation data. We repeated the model 
development process in each bootstrap sample (as out-
lined above, including variable selection) to produce a 
model, applied the model to the same bootstrap sample 
to quantify apparent performance, and applied the 
model to the original dataset to test model performance 
(calibration slope and C statistic) and optimism (differ-
ence in test performance and apparent performance). 
We then estimated the overall optimism across all mod-
els (for example, derive shrinkage coefficient=average 
calibration slope from each of the bootstrap samples).25 
To account for over-fitting during the development pro-
cess, we multiplied the original β coefficients by the 
uniform shrinkage factor in the final model. At this 
point, we re-estimated the intercept on the basis of the 
shrunken β coefficients to ensure that overall calibra-
tion was maintained, producing a final model.
We applied our risk prediction model to each woman 
in the external validation cohort on the basis of the pres-
ence of one or more risk factors (box 1). We examined the 
performance of this final model (in the original English 
data and then in the Swedish data) in terms of discrimi-
nation by calculating the C statistic. We examined cali-
bration by plotting agreement between predicted and 
observed risks across tenths of predicted risk. For this 
external validation in Swedish data, we recalibrated the 
intercept on the basis of the incidence of venous throm-
boembolism and mean centring all predictors; however, 
we also assessed the performance of our model by 
applying the intercept from the English data because of 
the similar baseline venous thromboembolism risk in 
both populations. We applied the existing UK guidelines 
to the English data and the Swedish guidelines to the 
Swedish data to assess the number of women who qual-
ified for pharmacological thromboprophylaxis.5 6 
box 1: risk prediction model
Risk score from a logistic regression model to predict venous thromboembolism (VTE) in 
the first six weeks postpartum. Risk score=−9.103+0.94×(0.227smoker+1.221varicose 
veins+0.848comorbidities (cardiac, renal, or inflammatory bowel disease)+0.721pre-
eclampsia/eclampsia+0.421diabetes+0.502postpartum haemorrhage+1.151stillbirth+ 
1.097postpartum infection+(0.750emergency section/0.563elective section)+(0.165parity 
of 1/0.481parity of 2/0.566parity of ≥3)–0.0000798age at delivery3+0.0000214(age at 
delivery3 log (age at delivery))+0.00026641BMI3−0.0000650(BMI3 log (BMI))−22156315 
infant birth weight−2+3455223.4(infant birth weight−2 log (baby’s birth weight)))
All variables are coded as binary (0 or 1 for absence or presence of a risk factor), except for 
age, body mass index (BMI), and birth weight. These three variables were transformed on 
the basis of fractional polynomial regression (first degree) analysis. The value −9.103 is 
the intercept, and other numbers are the estimated regression coefficients for the 
predictors, which indicate their mutually adjusted relative contribution to the outcome 
risk. The regression coefficients represent the log odds ratio for a change of 1 unit in the 
corresponding predictor. The predicted risk of VTE=1/1+e−riskscore.
Example 1—A 20 year old nulliparous woman who had an emergency caesarean 
section and has a BMI of 32. She had no history of comorbidities, developed no 
pregnancy related complications, and delivered a baby with birth weight of 3368 g. 
She has a predicted risk of 0.11% of developing a VTE within the first six weeks of 
delivery. Interpretation: if 1000 women with the same risk factors are followed, one 
will develop VTE within six weeks of childbirth.
Example 2—A 36 year old woman with a BMI of 45 who underwent an emergency 
caesarean section complicated with postpartum haemorrhage and infection. She had 
a history of cardiac disease and varicose veins. Her predicted VTE risk is 4.9% within 
the first six weeks of delivery. Interpretation: if 1000 women with the same risk factors 
are followed, 49 will develop VTE within six weeks of childbirth.
log=natural logarithm
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This was based on the clinical risk factors we were able 
to measure reliably in our data. We then calculated the 
sensitivity, specificity, and positive predictive value for 
those women and compared them with the same propor-
tion of women with the highest risk based on our predic-
tion model. We repeated this analysis after excluding 
women already given a prescription for thromboprophy-
laxis. We also formally compared the number of venous 
thromboembolism events that were identified and 
missed, on the basis of our prediction model and exist-
ing guidelines, by using McNemar’s test for discordant 
pairs, in both the English and Swedish data. Finally, we 
carried out a decision curve analysis to compare our pre-
diction model with the existing thromboprophylaxis 
guidelines in the English and Swedish data.24 26  This 
analysis assumes that the threshold probability of the 
disease at which a patient would opt for intervention is 
informative on how the patient weighs the relative harm 
of a false positive or a false negative prediction. This is 
then used to calculate the net benefit of the model across 
a wide range of threshold probabilities.24  The most basic 
interpretation of a decision curve is that the model with 
the highest net benefit at a particular threshold has the 
highest clinical value.26
We used Stata version 13 for all statistical analyses. 
This study was conducted and reported in line with the 
Transparent Reporting of a multivariate prediction 
model for Individual Prediction or Diagnosis (TRIPOD) 
guidelines.25
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community.
Results
study participants
In our derivation cohort from England, we analysed 
information on 321 415 women with 433 353 delivery epi-
sodes that resulted in live births or stillbirths with a 
complete six weeks of post-delivery follow-up. Our val-
idated Swedish cohort had information on 498 918 
women with 662 387 deliveries. Table 1 summarises the 
basic characteristics of the study population. Broadly, 
women in both cohorts had similar pre-pregnancy body 
mass index, delivery age, and prevalence of comorbidi-
ties (with the exception of varicose veins). Compared 
with England, women in Sweden were less likely to 
smoke and had fewer delivery related complications.
Model development, performance measure, and 
validation
In the English development dataset, 312 venous throm-
boembolism events occurred during the first six weeks 
postpartum with an absolute rate of 7.2 per 10 000 deliv-
eries. Univariable associations between postpartum 
venous thromboembolism and potential predictors are 
listed in supplementary table C. Of the 22 candidate pre-
dictors, 15 were statistically significantly associated 
with venous thromboembolism in our final 
 multivariable model (table 2 ). Table 3  shows apparent 
and internal validation performance statistics of our 
risk prediction model. After adjustment for optimism, 
our final risk prediction model was able to discriminate 
postpartum women with and without venous 
 thromboembolism with a C statistic of 0.70 (95% confi-
dence interval 0.67 to 0.73). The agreement between the 
observed and predicted proportion of events showed 
excellent apparent calibration (fig 1 , top), but a uniform 
shrinkage factor of 0.94 was needed to adjust predictor 
coefficients in the final model for optimism (table 3 ). 
Box 1 shows our final risk prediction model, which we 
integrated in a windows based calculator. Figure 2 
shows a screen shot of our windows based risk calcula-
tor, which can be integrated into a designated website 
or a general practice/hospital computer system.
table 1 | basic characteristics of study populations. values are numbers (percentages) 
unless stated otherwise
variable
Derivation cohort 
(england) 
(n=433 353)
validation cohort 
(sweden) 
(n=662 387)
Venous thromboembolism events 315 (0.07) 521 (0.08)
Social and demographic factors:
 Mean (SD) age at delivery, years 29.38 (5.90) 30.32 (5.23)
 Mean (SD) body mass index* 24.05 (4.90) 24.62 (4.57)
 Smoker† (latest record before delivery) 93 264 (21.52) 32 502 (4.91)
 Deliveries in 2004 or thereafter 280 498 (64.73) 662 387 (100)
Comorbidities‡:
 Varicose veins 10 935 (2.52) 5156 (0.78)
 Heart disease 4431 (1.02) 5072 (0.77)
 Kidney disease 4168 (0.96) 6666 (1.01)
 Inflammatory bowel disease 2126 (0.49) 5285 (0.80)
Pregnancy complications:
 Pre-eclampsia/eclampsia 9966 (2.30) 24 013 (3.63)
 Diabetes§ 14 604 (3.37) 14 948 (2.26)
 Hypertension§ 41 300 (9.53) 7980 (1.20)
Parity:
 Nulliparous¶ 244 233 (56.36) 293 176 (44.26)
 1 130 121 (30.03) 242 341 (36.59)
 2 38 599 (8.91) 88 803 (13.41)
 ≥3 20 400 (4.71) 38 067 (5.75)
Delivery characteristics/complications:
 Preterm birth (<37 weeks) 31 526 (7.27) 31 728 (4.79)
 Postpartum haemorrhage 42 978 (9.92) 48 383 (7.30)
 Spontaneous/assisted vaginal delivery 328 416 (75.78) 547 654 (82.68)
 Elective caesarean section 44 143 (10.19) 58 012 (8.76)
 Emergency caesarean section 60 794 (14.03) 56 721 (8.56)
 Multiple delivery (twins or more) 6550 (1.51) 9308 (1.41)
 Stillbirth 1972 (0.46) 2286 (0.35)
 Puerperal acute infection 13 681 (3.16) 48 383 (7.30)
 Infant’s mean (SD) birth weight**, g 3368.35 (596.80) 3519.80 (581.9)
Missing information:
 Infant birth weight 87 305 (20.14[20.15?]) 930 (0.14)
 Body mass index 98 868 (22.81) 57 173 (8.63)
*Pregnancies with missing pre-pregnancy body mass index: 23% (England), 8.6% (Sweden).
†Latest smoking record before delivery.
‡Comorbidities recorded ever before delivery; for specific disease group for comorbidities, see supplementary 
table A.
§Including gestational and pre-existing.
¶Antenatal parity.
**Pregnancies with missing infant birthweight information: 20% (England), 0.1% (Sweden).
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external validation
In our Swedish cohort, 521 women had postpartum 
venous thromboembolism with an absolute rate of 7.9 per 
10 000 deliveries. Applying our final risk prediction model 
(box 1) to the independent population after recalibration 
of the intercept gave a C statistic of 0.73 (0.71 to 0.75) and 
excellent calibration (fig 1 , bottom; supplementary figure 
A), with the calibration slope only slightly above 1 (table 
3). The mean predicted risk of venous thromboembolism 
based on our model was calculated to be 0.08% 
(min=7.73×10−13, max=12.9%). Box 1 gives two clinical 
examples of the application of our risk prediction model.
Comparing prediction models with existing 
guidelines
According to the UK’s postpartum thromboprophylaxis 
guideline,5  35% of women in the English data qualified 
for pharmacological thromboprophylaxis for at least 10 
days after delivery. The sensitivity and positive predictive 
value of the UK guideline based on our data were calcu-
lated to be 63% and 0.13% respectively. Applying our pre-
diction model to identify this proportion of women (that 
is, 35% of women would qualify, which related to having 
a predicted absolute risk threshold of 6.3 per 10 000 
deliveries) resulted in slightly higher sensitivity (68%) 
and positive predictive value (0.14%) (table 4). In the 
Swedish population, 6% of the postpartum women qual-
ified for pharmacological thromboprophylaxis on the 
basis of national guidelines. The sensitivity and positive 
predictive value were calculated to be 21% and 0.26% 
respectively. Identifying this proportion of postpartum 
women on the basis of our model (that is, 6% qualifying, 
which related to an absolute risk threshold of 18 per 
10 000 deliveries) resulted in a sensitivity of 30% and a 
positive predictive value of 0.38%. McNemar’s test for 
discordant pairs comparing venous thromboembolisms 
identified using our prediction model and the existing 
guidelines was statistically significant in both the 
English (P=0.02) and Swedish (P<0.001) cohorts. These 
results remained virtually unchanged when we excluded 
1% and 3% of women who were given pharmacological 
thromboprophylaxis in the English and Swedish data 
(supplementary table D). The performance of our model 
at various arbitrary thresholds is shown in supplemen-
tary table E. Finally, for each modelled threshold proba-
bility of venous thromboembolism, our model gave 
higher net benefit than the existing guidelines (supple-
mentary figures B and C).
discussion
We have developed a new risk prediction model to cal-
culate the absolute risk of venous thromboembolism 
during the first six weeks postpartum in a large repre-
sentative sample of postpartum women in England. We 
then externally validated this model in a Swedish 
national cohort. Overall, our prediction model had 
excellent calibration and useful discrimination, with a 
C statistic of greater than 0.70 in both the English and 
Swedish data. Our risk prediction model performed bet-
ter than the current UK and Swedish national thrombo-
prophylaxis guidelines in terms of sensitivity and 
positive predictive value at similar thresholds on the 
basis of the risk factors that we were able to capture reli-
ably in the women’s medical/pregnancy records.
strength and limitations of study
Our risk prediction algorithm has several advantages 
over those in use in many developed countries. 
table 2 | Final multivariable analysis for venous thromboembolism risk within six weeks 
of delivery in derivation cohort
variable
Model 1 (based on 
backwards elimination): 
odds ratio* (95% Ci) β coefficients
Smoker (latest record before delivery) 1.25 (0.97 to 1.62) 0.22684105
Varicose veins 3.39 (2.25 to 5.10) 1.2210805
Comorbidities (heart, kidney, or 
inflammatory bowel disease)
2.33 (1.47 to 3.71) 0.8476927
Pre-eclampsia/eclampsia 2.06 (1.32 to 3.20) 0.72127433
Diabetes 1.52 (0.97 to 2.39) 0.42119233
Nulliparous (antenatal) Reference  –
Parity 1 1.18 (0.91 to 1.53) 0.16456948
Parity 2 1.62 (1.13 to 2.33) 0.48143018
Parity 3 or more 1.76 (1.56 to 2.68) 0.5664196
Postpartum haemorrhage 1.65 (1.21 to 2.24) 0.50183134
Spontaneous/assisted vaginal delivery Reference  –
Elective caesarean section 1.76 (1.26 to 2.44) 0.56321456
Emergency caesarean section 2.11 (1.60 to 2.80) 0.75035197
Stillbirth 3.16 (1.29 to 7.73) 1.1514008
Postpartum infection 2.99 (2.07 to 4.33) 1.0969922
Fractional polynomial transformed
Age^3 – −0.00007986
Age^3×ln (age) – 0.00002147
BMI^3 – 0.00026641
BMI^3×ln (BMI) – −0.00006501
Infant birth weight^−2 – −22156315
Infant birth weight^−2×ln (birth weight) – 3455223.4
Constant† – −9.103121
Multiple imputation was carried out for missing body mass index (BMI) and birthweight data (10 imputations). 
Age was included in model as a priori predictor. Predictors were retained in model at 10% level of significance.
*For binary variables, odds ratio is based on women without particular risk factor under study.
†Average across population. Constant was re-estimated after adjustment of model for optimism to ensure that 
overall calibration was maintained.
table 3 | Model diagnostics (with 95% Ci)
Measure apparent performance* test performance† average optimism‡ Optimism corrected§
external validation 
(swedish data)
C statistic¶ 0.72 (0.69 to 0.75) 0.70 (0.70 to 0.71) +0.020 0.70 (0.67 to 0.73) 0.73 (0.71 to 0.75)
Calibration slope 1.00 (0.88 to 1.11) 0.94 (0.93 to 0.95) +0.061 0.94 (0.81 to 1.04) 1.11 (1.01 to 1.20)
*Refers to performance estimated directly from dataset that was used to develop prediction model.
†Determined by developing model in each bootstrap sample (100 samples with replacement), calculating performance (bootstrap performance), and applying bootstrap model in original sample.
‡Average difference between model performance in bootstrap data and test performance in original dataset.
§Subtracting average optimism from apparent performance.
¶Probability that for any randomly selected pair of women with and without venous thromboembolism (VTE), women with VTE had higher predicted risk.24 Value of 0.50 represents no 
discrimination and 1.00 represents perfect discrimination.
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The model is based on absolute risks determined and 
validated in two very large and independent popula-
tions.27  It is built from easily available clinical and 
demographic variables, implying that it can be straight-
forwardly applied in clinical practice and is readily 
amenable to further external validation in many coun-
tries that have routine data available for such a pur-
pose. Although our model equation may seem 
complicated compared with the existing thrombopro-
phylaxis guidelines, it can be easily integrated to a user 
friendly online calculator to be implemented in prac-
tice, being not dissimilar to those for QThrombosis.28
We found that less than 1% and 3% of women were 
given pharmacological thromboprophylaxis during the 
postpartum period in the English and Swedish data 
respectively. Although the performance of our model 
remained unchanged when we excluded women 
already given thromboprophylaxis, we have probably 
underestimated this proportion of women in the 
English data owing to unavailability of prescriptions 
emanating from secondary care. We believe, however, 
that thromboprophylaxis practices would be unlikely to 
have a huge effect on our estimates, as the risk of 
venous thromboembolism is significantly high well 
beyond the recommended intervention period of up to 
seven days29  (guideline changed to 10 days in 20155 ) 
after delivery for the vast majority of women at high 
risk.30  Furthermore, evidence suggests inadequate use 
of thromboprophylaxis,31 32  a belief supported by the 
finding of no significant change in the incidence of 
postpartum venous thromboembolism over time in our 
English data along with the recent increase in national 
venous thromboembolism related deaths observed in 
the UK.2 33
Although our model has excellent calibration across 
the observed spectrum of absolute predicted risks, this 
spectrum mainly includes predicted risks that are small 
even for women with multiple risk factors. However, a 
large portion of these women qualify for pharmacologi-
cal thromboprophylaxis on the basis of these small 
risks according to the current guidelines. This is 
because venous thromboembolism is the leading cause 
of direct maternity mortality in the UK, and venous 
thromboembolism related death may be prevented 
through targeted thromboprophylaxis. Our model 
enables prediction of postpartum venous thromboem-
bolism at an individual level, which is an improvement 
on the currently used un-validated ordinal point based 
system that categorises women into low, intermediate, 
and high risk groups.
Although our model identifies more venous thrombo-
embolism events than the current UK and Swedish 
guidelines and has been externally validated, it also 
missed 32% of postpartum venous thromboembolisms. 
This is not surprising given that a previous nationwide 
study from the UK reported that only 70% of women 
with antenatal pulmonary embolism had classic risk 
factors for venous thromboembolism. However, as a 
screening tool, our prediction model will have import-
ant implications for identifying those in whom throm-
boprophylaxis may be recommended.
We excluded women with a history of venous throm-
boembolism from our study as they represent a small 
proportion of women for whom the decision to give 
anticoagulants is less controversial. We also did not 
include information on a variety of risk factors (for 
example, protein C and S deficiency, factor V Leiden 
and prothrombin gene mutation, and family history of 
venous thromboembolism) in our model. However, by 
excluding women with a history of venous thromboem-
bolism from our study, we may have limited its effect on 
our estimates. Furthermore, universal screening for 
some of those risk factors (such as factor V Leiden) is 
not routinely recommended in pregnant women, so 
pragmatically it cannot be used to predict the risk of 
first venous thromboembolism in the wider general 
population. The current RCOG thromboprophylaxis 
guideline recommends risk assessment for venous 
thromboembolism intrapartum or immediately after 
childbirth.5 Thus our risk assessment tool can be used 
to quantify risk of venous thromboembolism during 
that period. However, our prediction model should not 
be used for women with one or more risk factors not 
measured in our model (for example, immobilisation 
due to fracture or in general) and should not be relied 
on to the exclusion of clinical judgment for prescribing 
thromboprophylaxis.
We acknowledge that our model does not take into 
account disease severity for specific comorbidities 
owing to data limitations and inadequate number of 
venous thromboembolism events leading to a lack of 
power to stratify on disease severity, if known. How-
ever, our prediction model is in line with the existing 
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Fig 1 | assessing calibration in english derivation cohort 
(top) and swedish validation cohort (bottom). intercept 
was re-estimated for swedish population on basis of 
incidence of venous thromboembolism and mean centring 
all predictors
bmj.i6253.indd   6 30-11-2016   12:14:20 PM
the bmj | BMJ 2016;355:i6253 | doi: 10.1136/bmj.i6253
RESEARCH
7
guidelines that also do not take into account disease 
severity. Women who become pregnant are generally 
healthier and have lower prevalence of pre-existing 
comorbidities compared with the general population. 
In our study, the prevalence of heart, kidney, and 
inflammatory bowel disease was around 1% (even after 
use of our broad definitions). Thus the proportion of 
women experiencing severe heart and kidney disease 
during pregnancy will be even lower, and these women 
will probably be cared for very differently from those 
with well controlled comorbidities. We also believe that 
whereas in theory our model could be improved by 
ascertaining more detail on the severity of risk factors, 
this would negatively affect the ability to apply this in 
practice where information on risk factors will need to 
be obtained accurately in a relatively short clinical 
assessment.
Comparison with other studies
Although several studies have examined risk factors for 
venous thromboembolism during the postpartum 
period, studies specifically designed to develop and 
Fig 2 | screenshot of windows based risk prediction program. based on hypothetical data and coefficients
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 validate the risk prediction model are scarce. Previously, 
two risk models were constructed using Swedish data. 
One was based on a weighted risk score for exposures 
associated with at least a fivefold increase in risk of 
venous thromboembolism6 34 ; the other, an individual-
ised risk assessment tool, was based on absolute risks of 
venous thromboembolism.35  Both risk models failed to 
include some of the common clinical risk factors such as 
postpartum haemorrhage, type of caesarean section, 
and puerperal infection, which are important predictors 
of venous thromboembolism.5  Furthermore, the first 
model (weighted risk score) was based on a small num-
ber of pregnant women (<2500) from a single centre that 
does not comprehensively inform the performance of 
the model. The UK, Sweden, and Canada use a points 
based algorithm to identify high risk postpartum women 
for pharmacological thromboprophylaxis.4-6  The US 
guidelines are more conservative and advise against the 
routine use of pharmacological thromboprophylaxis.3 
These guidelines do not take into account the individu-
alised absolute risk of venous thromboembolism based 
on women’s complex clinical risk profile, and nor have 
they been externally validated, which is crucial to facili-
tate their translation into practice.
Conclusion and policy implications
Our study has three important implications for clinical 
practice. Firstly, our prediction model can be used as a 
tool to identify women at high risk on the basis of their 
absolute predicted risk of venous thromboembolism 
within the first six weeks postpartum. The algorithm is 
based on standard clinical variables that are likely to be 
available at the point of childbirth and that could be 
readily integrated into secondary care computer sys-
tems or developed into an app for handheld devices for 
ease of use. Secondly, our prediction model performed 
better than the current UK and Swedish thrombopro-
phylaxis guidelines (based on the risk factors recorded 
in data registries) in terms of identifying a higher 
 proportion of venous thromboembolism events. Finally, 
our risk prediction model could be used to establish 
new treatment thresholds in clinical practice through 
consensus development of national guidelines. For 
example, the Swedish approach of targeting 6% of 
women may be a template for the UK, as the incidence 
of venous thromboembolism does not vary much 
between the two countries. On the other hand, the cur-
rent Swedish threshold may be too conservative and 
may be leading to under-treatment. Naturally, such 
changes in guidelines will need to take into account the 
perspectives of the healthcare providers, practitioners, 
and women in each country and consider the potential 
benefits and harms of any threshold that is chosen, 
which is beyond the scope of this study.
Contributors: AAS, LJT, JW, KMF, and MJG conceived the idea for the 
study. OS, RDR, and JFL also made important contributions to the 
design of the study. AAS did the data management and analysis and 
wrote the first draft of the manuscript. OS and CNP provided clinical 
input at all stages of the project. All authors were involved in the 
interpretation of the data, contributed towards critical revision of the 
manuscript, and approved the final draft. AAS had full access to all of 
the data and had final responsibility for the decision to submit for 
publication. AAS and MJG are the guarantors.
Funding: This project was funded by JW’s University of Nottingham/
Nottingham University Hospital’s NHS Trust senior clinical research 
fellowship. OS was supported by the Swedish Research Council 
(project No 2013-2429).
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf (available on 
request from the corresponding author) and declare: funding for the 
project as described as above; CNP was co-developer of the currently 
available guidelines on venous thromboembolism prophylaxis in 
pregnancy issued by the Royal College of Obstetricians and 
Gynaecologists (green top guideline 37a), has received honorariums 
for giving lectures from Leo Pharma and Sanofi Aventis (makers of 
tinzaparin and enoxaparin low molecular weight heparins used in 
obstetric thromboprophylaxis), and has received payment from Leo 
Pharma for development of an educational “slide kit” about obstetric 
thromboprophylaxis; no other relationships or activities that could 
appear to have influenced the submitted work.
Ethical approval: This project was approved by the independent 
scientific advisory committee (reference number 10_193R) for the 
English data and by the ethics review board in Stockholm (reference 
number 2013/2229-31/1) for the Swedish data.
table 4 | Comparing current guidelines with risk prediction model
statistics
english data: total no postpartum 
women=433 353; total no vte 
events=312 (imputed results)
swedish data: total no pregnancies=662 387; total no vte 
events=521 (imputed results)
Women given 
thromboprophylaxis 
based on rCOg 
postnatal 
thromboprophylaxis 
guidelines*
risk prediction 
model (england): 
top 35% cut-off 
(threshold=6.3 
per 10 000 
deliveries)
Women given 
thromboprophylaxis 
based on swedish 
national guidelines†
risk prediction 
model (sweden): 
top 6% cut-off 
(threshold=18 per 
10 000 deliveries)
risk prediction 
model (sweden): 
top 35% cut-off 
(threshold=7.2 
per 10 000 
deliveries)
Total No (%) postpartum women warranting thromboprophylaxis 149 402 (34.5) 149 402 (34.5) 41 254 (6.2) 41 254 (6.2) 231 835 (35)
Observed VTE events‡ 197 212 109 158 355
Mean predicted risk per 10 000 pregnancies 12.3 13.0 25.8 31.6 14.2
Sensitivity§, % (95% CI) 63.1 (57.5 to 68.5) 67.9 (62.5 to 73.1) 20.9 (17.5 to 24.7) 30.3 (26.4 to 34.5) 68.1 (63.9 to 72.1)
Positive predictive value¶, % (95% CI) 0.13 (0.11 to 0.15) 0.14 (0.12 to 0.16) 0.26 (0.21 to 0.31) 0.38 (0.32 to 0.45) 0.15 (0.13 to 0.17)
Specificity**, % (95% CI) 65.6 (65.4 to 65.7) 65.6 (65.4 to 65.7) 93.8 (93.7 to 93.8) 93.8 (93.7 to 93.9) 65.1 (64.9 to 65.2)
*Women with either two low risk factors (varicose veins, age >35 years, overweight, body mass index (BMI) 30-39, parity ≥3, smoker, puerperal infection, elective caesarean section, multiple 
delivery, preterm birth, stillbirth, pre-eclampsia/eclampsia, or postpartum haemorrhage) or one high risk factor (comorbidities (inflammatory bowel disease (IBD), heart disease, kidney 
disease), BMI ≥40, or emergency caesarean section)).
†Women with two clinical risk factors (elective caesarean section, age ≥40 years, BMI ≥30, or any comorbidities (heart disease, IBD, or kidney disease)).
‡In women warranting thromboprophylaxis.
§Percentage of true positive venous thromboembolism (VTE) cases correctly identified on basis of current thromboprophylaxis guidelines/risk prediction model.
¶Percentage of women without VTE diagnosis correctly identified on basis of thromboprophylaxis guidelines/risk prediction model.
**Likelihood that women above treatment threshold will develop VTE.
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